Critical appraisal of belatacept for prophylaxis of rejection in kidney transplant patients

Spencer T Martin1
Demetra Tsapepas1
Steven Gabardi2–5
Anil Chandraker2,3

1Department of Pharmacy, New York-Presbyterian Hospital, New York City, NY, USA; 2Harvard Medical School, Boston, MA, USA; 3Renal Division, Department of Pharmacy Services, Department of Transplant Surgery, Brigham and Women’s Hospital, Boston, MA, USA

Abstract: Belatacept (LEA29Y) is an intravenous biologic for long-term maintenance immunosuppressive therapy in renal transplant recipients. It is currently being reviewed by the United States Food and Drug Administration (FDA) as a prophylactic therapy against acute cellular rejection (ACR) in de novo renal transplant recipients. To provide an in-depth review of the pharmacology, clinical efficacy, safety, and applications of belatacept, a MEDLINE database search was performed for all English-language articles evaluating the pharmacology and efficacy of belatacept, as well as abstracts from recent scientific meetings. Belatacept is a potent inhibitor of B7 binding to CD28, a potent T-cell co-stimulatory signal. The B7 ligands are found on the surface of antigen-presenting cells, specifically B7-1 (CD80) and B7-2 (CD86). CD80 and CD86 are essential ligands for CD28, a critical component of costimulation in the three-signal transplant model of T-cell activation. Belatacept has proven noninferiority compared with calcineurin-inhibitor (CNI)-based regimens in the incidence of patient and allograft survival. However, the incidence and severity of ACR has been shown to be increased in patients receiving belatacept therapy. Although rates of ACR are increased in patients receiving belatacept, an overall improvement in allograft function has been described with average improvements in glomerular filtration rates of up to 12–15 mL/min higher than CNI-based regimens. The side-effect profile of belatacept has been shown to be similar or improved compared with CNI therapy; however, the risk of malignancy, specifically post-transplant lymphoproliferative disorder is notably higher. Because of the marked increase in the risk of malignancy and ACR, approval of belatacept by the FDA will rely on more robust data from long-term follow-up of currently available data.

Keywords: renal transplantation, immunosuppression

Introduction

Considerable gains in the field of immunology, specifically the understanding of cellular immunity, have significantly advanced the field of solid organ transplant (SOT). Researchers and clinicians have strived to adequately inhibit the process required for T-cell activation and proliferation without facilitating infectious complications and pharmacologic toxicities. The costimulation pathway is a well known and essential component in T-cell activation; however, current immunosuppressive strategies in SOT do not target it. The B7 family of ligand receptors, B7-1 (CD80) and B7-2 (CD86), found on the surface of antigen-presenting cells (APCs) bind to CD28, a disulfide-linked homodimeric transmembrane protein required for T-cell activation and proliferation. Development of agents that target this essential interaction may result in a more selective process for prophylaxis against allograft rejection while sparing other cellular systems and potential toxicities.
Abatacept (CTLA4-Ig), an agent approved for use in rheumatoid and polyarticular juvenile idiopathic arthritis, was developed to inhibit the B7 ligands found on APCs. This agent was assessed in animal models of organ transplant. After initial failures, a more potent derivative of abatacept, belatacept (LEA29Y), was developed.

Belatacept represents a paradigm shift in immunosuppressive maintenance therapies for organ transplantation. If approved by the United States Food and Drug Administration (FDA), belatacept would be the first biologic agent marketed for use in long-term maintenance regimen in SOT. To be considered an attractive option for transplant, a biologic agent must overcome several barriers, including possessing the ability to inhibit the immune response in a nondepleting manner without creating excessive immunodeficiency, lacking initial and prolonged immunogenicity and the need for therapeutic drug monitoring (TDM), and offering a reasonable administration route and interval between doses. This manuscript aims to review the pharmacology, efficacy, safety, and clinical application of belatacept in renal transplantation.

We conducted a non-date-restricted MEDLINE search for English-language articles by using the following terms: “belatacept”, “LEA29Y”, “CTLA4-Ig”, “renal transplantation”, and “organ transplantation”. Data were available through to November 2010. Data from abstracts presented at scientific meetings were also included.

Pharmacology and pharmacokinetics
Belatacept is a derivative of its parent compound, abatacept.8,9 Use of abatacept as an immunosuppressive therapy in SOT was originally tested in mice with promising results.9 Unfortunately, follow-up in nonhuman primate models of renal transplantation yielded less impressive results.10,11 Both compounds have an antagonistic effect on the CD80 and CD86 ligands presented on the surface of APCs. CD80 and CD86 are considered a fundamental component of cellular immunity as the precursors to T-cell activation.7 In combination with the activation of the CD3 immunoglobulin on naïve T-cells, binding of CD28 on the surface of a naïve T-cell by CD80/86 results in the production of calcium-calciineurin, Ras-mitogen-activated protein kinase, and nuclear factor-κB.12 Aside from an increase in cytokine release, this pathway also promotes prolonged cell survival by enhancing the expression of anti-apoptotic molecules, preparation of cellular bioenergetic pathways for improved metabolic demand, and ultimately clonal expansion.13 Activation of CD3 via APC major-histocompatibility and antigen peptide presentation without costimulation, results in T-cell anergy. This unresponsive state begins a self-destruction cascade resulting in T-cell apoptosis.14,15

The development of belatacept for use in SOT was partially based on abatacept’s affinity to the CD80/86 receptors. Soluble CTLA-4 was found to have a 2500-fold higher affinity to CD80 than CD28 and a 500-fold higher affinity to CD86 than CD28.9 Although the higher affinity to CD80/86 compared with CD28 is impressive, with use of CTLA-4lg, the increase in the compound’s affinity to CD80 results in a 100-fold decrease in the overall affinity to CD86, resulting in an incomplete and unequal inhibition of T-cell costimulation.16,17 The differences in affinity and abatacept’s poor outcomes in animal models of transplant led to the development of a more potent agent with higher selectivity to the CD80/86 ligands on APCs. Belatacept is the result of altering two amino acids in the CD80/86 binding portion of the abatacept compound. This slight change in chemistry resulted in a 4-fold increase in binding affinity to CD86 and a 2-fold increase in binding affinity to CD80 compared with abatacept. Overall, the increase in belatacept’s affinity to both CD80/86 results in a 10-fold increase in the ability to inhibit T-cell activation when compared in vitro.9 The improvement demonstrated in vitro directly correlated with improved outcomes in the nonhuman primate model for renal transplantation.9

Saturation of the CD80/86 ligands by belatacept was determined while patients were enrolled in Phase II and III clinical trials.18 Free CD80/86 was determined prior to and after belatacept infusions to determine the degree of saturation. Inhibition of each ligand was found to be concentration dependent. However, saturation at the CD80 site occurred at a belatacept concentration of 0.1 µg/mL, and CD86 saturation occurred at a concentration of 1.0 µg/mL. It was concluded that appropriate immune suppression would most likely rely on achieving levels of 1.0 µg/mL so that both CD80 and CD86 are adequately inhibited. Incomplete saturation may result in a decreased ability to inhibit costimulation, resulting in T-cell activation and subsequent acute cellular rejection (ACR). The authors concluded that occupancy of CD86 by belatacept may influence the overall level of immunosuppression achieved with belatacept in the clinical setting.18 Currently, no clinical trials have adopted this method as a means of assessing or guiding belatacept therapy.
In regards to maintenance immunosuppression, belatacept’s route-of-administration is unique as an intravenous (IV) infusion. The FDA is currently reviewing a less-intensive (LI) dosing regimen for belatacept compared with a more-intensive (MI) dosing schedule. The LI regimen is dosed at 10 mg/kg on post-operative day (POD) 1 and 5, then on weeks 2, 4, 8, 10, 12, 16, 20, and 24, and transitioned to 5 mg/kg every 4 weeks after. The IV route requires that patients have access to an infusion-center or home infusion services, or be capable of traveling to their transplant center for the infusion. Although this specific requirement may be a barrier to therapy for some patients, there is a potential benefit in relation to assured adherence to the belatacept portion of therapy. With appropriate monitoring, a missed infusion of belatacept can immediately result in clinician awareness and appropriate follow-up to ensure administration.

Pharmacokinetic data for belatacept were generated from 984 patients participating in Phase I, II, and III clinical trials. The half-life of belatacept is about 11 days, allowing for prolonged time intervals between required infusions. Belatacept is defined by a linear two-compartment model with zero-order IV infusion and first-order elimination. Weight-based dosing for belatacept is supported by increased clearance and volume of central compartment with increasing baseline bodyweight when dosed between 5 and 10 mg/kg. Demographic parameters, including gender, race, age, renal and hepatic function, and diabetes, were not found to impact belatacept pharmacokinetics.

### Clinical efficacy

In a Phase II trial, Vincenti et al demonstrated noninferiority of belatacept to cyclosporin for preventing clinically suspected biopsy-proven acute rejection (BPAR) in adult renal transplant recipients (RTRs) at 6 months (Table 1). The study was an open-label, partially blinded, randomized, parallel-group, multicenter trial conducted between March 2001 and December 2003. A total of 218 non-HLA identical adult patients receiving a living or deceased donor renal transplant were included in the study. Higher-risk patients (prior renal transplant, historical peak panel-reactive antibody [PRA] >20%) who were considered at increased risk for ACR could make up no more than 10% of the study population. Patients were excluded from participation if the etiology of their end stage renal disease was from a disease that could recur in the allograft, had active infection with hepatitis B, hepatitis C, or HIV (human immunodeficiency virus), a history or evidence of malignancy, positive T-cell complement-dependent cytotoxicity crossmatch, or a history of rejection.

<table>
<thead>
<tr>
<th>Author Year Follow-Up</th>
<th>Intervention</th>
<th>ACR n (%)</th>
<th>Patient Survival n (%)</th>
<th>Graft Survival n (%)</th>
<th>Malignancy n (%)</th>
<th>PTLD n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vincenti19 2005 12 months</td>
<td>MI Belatacept (n = 74)</td>
<td>5 (7)</td>
<td>73 (99)</td>
<td>71 (96)</td>
<td>4 (5)*</td>
<td>3 (4)*</td>
</tr>
<tr>
<td></td>
<td>LI Belatacept (n = 71)</td>
<td>4 (6)</td>
<td>71 (100)</td>
<td>70 (99)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td></td>
<td>Ciclosporin (n = 73)</td>
<td>6 (8)</td>
<td>69 (93)</td>
<td>71 (97)</td>
<td>2 (3)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>BENEFIT-EXT; Durrbach24 2010 12 months</td>
<td>MI Belatacept (n = 184)</td>
<td>33 (18)</td>
<td>176 (96)</td>
<td>167 (91)</td>
<td>5 (3)c</td>
<td>2 (1)c</td>
</tr>
<tr>
<td></td>
<td>Ciclosporin (n = 184)</td>
<td>31 (18)</td>
<td>171 (98)</td>
<td>159 (91)</td>
<td>5 (3)c</td>
<td>3 (2)c</td>
</tr>
<tr>
<td></td>
<td>Belatacept + Mycophenolate Mofetil (n = 33)</td>
<td>4 (12)</td>
<td>32 (97)</td>
<td>31 (94)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td></td>
<td>Belatacept + Sirolimus (n = 26)</td>
<td>1 (4)</td>
<td>26 (100)</td>
<td>24 (92)</td>
<td>1 (4)</td>
<td>0 (0)</td>
</tr>
<tr>
<td></td>
<td>Tacrolimus + Mycophenolate Mofetil (n = 30)</td>
<td>1 (3)</td>
<td>30 (100)</td>
<td>30 (100)</td>
<td>1 (3)</td>
<td>0 (0)</td>
</tr>
</tbody>
</table>

Notes: *Two additional patients developed PTLD 2 and 13 months after the trial end-date; †Two additional patients developed PTLD after the trial end-date at 12 months; ‡One additional patient developed PTLD after the trial end-date at 12 months.

Abbreviations: ACR, acute cellular rejection; LI, less intensive belatacept regimen; MI, more intensive belatacept regimen; PTLD, post-transplant lymphoproliferative disorder.
history of drug or alcohol abuse and psychotic illness, donors >60 years of age or donation after cardiac death (DCD), or a cold ischemia time >36 hours. All patients received basiliximab induction, 20 mg IV on POD 0 and 4, and maintenance therapy with 2 g/day mycophenolate mofetil, a corticosteroid taper (500 mg on POD 0 decreased to no less than 5 mg per day by month 4), and study drug. Patients were randomized to an MI belatacept regimen (0–6 months: 10 mg/kg on days 1, 5, 15, 29, 43, 57, 71, 85, 113, 141, and 169, followed by 7–12 months: 5 mg/kg every 4 or 8 weeks), an LI belatacept regimen (0–3 months: 10 mg/kg on days 1, 15, 29, 57, and 85, followed by 3–12 months: 5 mg/kg every 4 or 8 weeks), or cyclosporin (target trough level: 0–1 months: 150–400 ng/mL and 2–12 months: 150–300 ng/mL). All patients underwent protocol biopsies at baseline and month 12 and plasma clearance of iohexol was utilized to assess glomerular filtration rates (GFR) at 12 months.19

The primary endpoint of noninferiority in the prevention of ACR at 6 months was defined clinicopathologically as an increase in serum creatinine of 0.5 mg/dL along with findings on renal biopsy consistent with rejection.19 Incidence of ACR in each study group was similar and the inferiority margin of 20% was met within all three groups. ACR occurred in 7%, 6%, and 8% of patients in the MI belatacept group (n = 74), LI belatacept group (n = 71), and cyclosporin group (n = 73), respectively. Severe rejection episodes (Banff IIB) which required antithymocyte therapy occurred in 4%, 7%, and 3% of the MI, LI, and cyclosporin groups, respectively. Subclinical rejection at month 6 was more common in the LI belatacept group (20%) compared with the MI belatacept (9%) and cyclosporin groups (11%). No patients experienced ACR after the 6-month study period. Chronic allograft nephropathy was more prevalent in the cyclosporin group (24%) as compared with both the MI (29%) and LI (20%) belatacept groups. Measured GFR at 12 months was significantly higher in both belatacept groups; MI (66.3 mL/min) to cyclosporin (53.5 mL/min) (P = 0.01) and LI (62.1 mL/min) to cyclosporin (P = 0.04). Patient and graft survival were similar in all treatment groups at the end of the study.19

Long-term data on belatacept were evaluated in an open-label extension of this trial.21 Approximately 60% of patients enrolled in the original trial (MI = 56; LI = 46; cyclosporin = 26) remained in the extension analysis. Median follow-up during this period was 5 years (range: 1–7 years). Safety and efficacy outcomes were analyzed using combined MI and LI belatacept-treated patients because this study was not powered to detect a difference in outcomes between the two treatment arms. The average calculated GFR remained stable for belatacept-treated patients from month 12 to 60, 75.8 ± 20.1 mL/min and 77.2 ± 22.7 mL/min respectively but decreased in patients maintained on cyclosporin therapy from 74.4 ± 23.7 mL/min to 59.3 ± 15.3 mL/min. Patient and graft survival were 97% and 99% for belatacept-treated patients and 92% and 100% for cyclosporin treated patients. Late BPAR only occurred in the belatacept-treated patients (6%); two episodes in the MI group and four episodes in the LI group.21

A Phase III study of belatacept-based immunosuppression regimens versus cyclosporin in renal transplant recipients (BENEFIT) was a 3-year, randomized, active-controlled, partially blinded, parallel group, multicenter study conducted in 100 centers worldwide (Table 1).22 Treatment with two belatacept-based regimens were compared with a cyclosporin-based regimen evaluating three co-primary outcomes, a composite patient and graft survival, composite renal impairment endpoint and the incidence of ACR at 12 months. All adult RTRs receiving grafts from living or deceased donors with a cold ischemia time less than 24 hours were eligible for participation. Exclusion criteria included receiving a DCD or extended criteria donor (ECD), prior or concurrent nonrenal transplant, or having a PRA of >50% or >30% in patients being re-transplanted. Of the 666 patients transplanted, 526 completed the 12-month treatment phase.22

All patients received basiliximab induction, 20 mg IV on POD 0 and 4, and maintenance therapy with mycophenolate mofetil (2 g/day), and corticosteroids (500 mg on POD 0 and no less than 2.5 mg/day by POD 15) in addition to study drug.22 Patients were randomized in a 1:1:1 fashion to an MI belatacept regimen (10 mg/kg on days 1 and 5 and weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24, then 5 mg/kg every 4 weeks), an LI belatacept regimen (10 mg/kg on days 1 and 5, and weeks 2, 4, 8, and 12, then 5 mg/kg every 4 weeks), or cyclosporin (target trough level: 0–1 months: 150–300 ng/mL and 2–12 months: 100–250 ng/mL).22

Both belatacept regimens met the noninferiority margin of 10% as well as a more rigorous threshold of 5% for the coprimary endpoint of patient and graft survival compared with the cyclosporin group.22 Evaluation of the coprimary composite renal impairment endpoint demonstrated that renal function was superior in patients who were randomized to belatacept versus cyclosporin. The incidence of ACR at 12 months was 22% in the MI group, 17% in the LI group, and 7% in the cyclosporin group. The LI group was deemed noninferior for preventing ACR compared with
the cyclosporin by satisfying a 20% margin for comparison; however, the MI group exceeded the inferiority margin and was therefore statistically inferior to the cyclosporin group – more patients receiving belatacept MI experienced Banff grade IIB rejection episodes. The mean measured GFR was 13–15 mL/min higher in the belatacept group despite a higher incidence of BPAR. All patients underwent a protocol biopsy at week 52; however, the study advocated that investigators perform biopsies if there were reasons for clinical suspicion of rejection: unexplained rise in serum creatinine $\geq$25% from baseline, unexplained decrease in urine output, fever and graft tenderness, or serum creatinine that remained elevated for 14 days posttransplant.22

Extended criteria donors
The decline in availability of organs for transplantation has led to increased utilization of ECD to increase the donor pool. Accepting an ECD organ decreases transplant list waiting time and decreases a patient’s risk of cardiovascular complications that are associated with end-stage renal disease. However, ECD RTRs typically experience higher rates of delayed graft function (DGF), increased incidence of ACR, and generally experience decreased allograft survival time.21

A Phase III trial (BENEFIT-EXT) was developed to evaluate whether belatacept would provide similar patient and graft survival as well as superior renal function when used as first-line immunosuppression versus cyclosporin specifically in patients receiving ECD organs (Table 1).24 Adult patients who received a renal allograft from an ECD donor, defined as greater than or equal to 60 years of age; or 50 years of age or older with at least two risk factors including cerebral vascular accident, hypertension, or a serum creatinine $\geq$1.5 mg/dL; or an anticipated cold ischemia time of 24 hours or greater; or DCD. Patients were randomized to one of three groups: MI belatacept regimen (10 mg/kg on days 1 and 5, and weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24, then 5 mg/kg every 4 weeks); an LI belatacept regimen (10 mg/kg on days 1 and 5, and weeks 2, 4, 8, and 12, then 5 mg/kg every 4 weeks); or cyclosporin (0–1 months trough levels: 24–120 ng/mL then 2–12 months trough levels: 100–250 ng/mL) in a 1:1:1 fashion. All patients received basiliximab induction at the time of transplant (20 mg IV on POD 1 and 5) as well as mycophenolate mofetil (2 g/day in divided doses) and corticosteroids (500 mg on POD 0 tapered over 15 days to at least 2.5 mg/day) for maintenance immunosuppression in addition to the treatment arm to which they were randomized. Patients in the cyclosporin treatment group were allowed T-cell-depleting agents if DGF occurred. Mild rejection episodes were treated with corticosteroid pulses, and T-cell depleting agents were permitted as treatment for severe or resistant rejection.24

A total of 543 of the 578 patients randomized in this study were transplanted (MI = 184; LI = 175; cyclosporin = 184).24 Demographic parameters, as well as the percentage of patients with DGF, were similar between the three treatment groups. Both belatacept groups were found to be noninferior to cyclosporin for the composite primary end-point of patient and graft survival, the pre-specified noninferiority margin was 10%. Graft loss caused by ACR, thrombosis, or technical causes was similar between all groups. The co-primary composite end-point of renal impairment (GFR $<60$ mL/min at 12 months or a decrease of $\geq 10$ mL/min from postoperative months 3–12) was significantly improved in the MI belatacept-treatment group versus cyclosporin ($P = 0.0083$). Although improvement in renal function for the LI belatacept-group did not reach statistical significance, GFR in this group was 6–8 mL/min higher than the cyclosporin group. GFR improvement was noted despite the fact that patients in all treatment groups experienced DGF.24

Biopsy-proven chronic allograft nephropathy (45%–52% of patients) and severe chronic allograft nephropathy (4%–7% of patients) at 12 months was similar between all treatment groups.24 The 20% noninferiority margin for incidence of ACR in this study was achieved by both MI and LI belatacept groups. Of note, nearly all rejection episodes occurred within the first 6 months post-transplant, but more Banff IIB rejection episodes developed in the belatacept groups (MI = 9%; LI = 5%) when compared with cyclosporin (3%), and more patients in the MI belatacept group had more than one episode of rejection (n = 5) versus LI belatacept (n = 1) and cyclosporin group (n = 2).24

Steroid and calcineurin inhibitor avoidance
A 1-year, randomized, open-label, Phase II, multicenter trial was conducted to evaluate the efficacy and safety of tacrolimus-based immunosuppression versus two belatacept-based regimens where steroid and calcineurin inhibitor avoidance was attempted (Table 1).25 A total of 89 Epstein–Barr virus (EBV) seropositive adults receiving a primary living donor or standard criteria deceased donor kidney transplant were randomized in a 1:1:1 fashion to one of three treatment arms: 1) belatacept and mycophenolate mofetil 1000 mg twice daily (B+MMF; n = 33); 2) belatacept and sirolimus (B+SRL; n = 26); or 3) tacrolimus plus mycophenolate
mofetil (TAC+MMF; n = 30). Sirolimus goal trough levels in the B+SRL group were 7–12 ng/mL for the first 6 months post-transplant and 5–10 ng/mL for the remainder of the study. Patients receiving tacrolimus in the B+TAC group had goal troughs of 8–12 ng/mL for the first month post-transplant and 5–10 ng/mL for the remainder of the study. All patients received rabbit-antithymocyte globulin induction (6 mg/kg maximum) and withdrawal of corticosteroids by POD 4. Intravenous methylprednisolone was administered at doses of 500, 250, 125, and 60 mg on POD 1, 2, 3, and 4, respectively. Belatacept maintenance dosing was similar to previously described MI regimens: 10 mg/kg on POD 1 and 5, then once every 2 weeks through month 3, every 4 weeks through month 6, and 5 mg/kg every 4 weeks thereafter.25

The primary endpoint was incidence of ACR at 6 months, which occurred at a rate of 12%, 4%, and 3% in the B+MMF, B+SRL, and TAC+MMF groups, respectively.25

Most rejection episodes occurred within the first 3 months post-transplant; however, one episode in the B+MMF group occurred after month 6. The composite end-point of patient and graft survival was similar between treatment groups, 91%, 92%, and 100% in the B+MMF, B+SRL, and TAC+MMF groups, respectively. One patient in the B+MMF group died during the study period. Both the B+MMF and B+SRL group had two patients who experienced graft loss. The mean calculated GFR for each group was 63.6 ± 27.3 mL/min, 61.8 ± 30.7 mL/min and 54.0 ± 15.0 mL/min for the B+MMF, B+SRL, and TAC+MMF groups, respectively. CNI and steroid avoidance was successful in 73% of the B+MMF and 77% of the B+SRL treated patients, and steroid avoidance alone was achieved in 93% of TAC+MMF treated patients.25

Converting from a calcineurin inhibitor-based regimen to belatacept

Several studies have demonstrated that belatacept is as efficacious as CNIs in preventing acute rejection and is associated with improved outcomes in GFR for RTR. Substitution of belatacept for a CNI may have the ability to spare renal transplant patients from the nephrotoxic and cardiovascular side effects of CNIs. Results from a Phase II study to evaluate conversion from a CNI-based regimen to belatacept have been reported in abstract form.26 This randomized, open-label study included 171 RTRs, 6–36 months post-transplant, who were receiving CNI-based immunosuppression and had stable renal function (MDRD GFR ≥ 35 mL/min/1.73 m² and ≤75 mL/min/1.73 m²). Patients were randomized into one of two treatment groups: conversion to belatacept 5 mg/kg every 4 weeks with CNI discontinuation (n = 83); or continued CNI therapy (n = 88). All patients remained on other maintenance immunosuppressive agents they were taking: mycophenolate, sirolimus, azathioprine, and corticosteroids.26

At month 12, the primary outcome of mean change in MDRD GFR from baseline increased by 7.0 mL/min ± 11.99 in the belatacept group and by 2.1 mL/min ± 10.34 in the CNI group.26 Six patients (7%) who underwent belatacept conversion experienced an ACR episode within the first 6 months compared with none in the CNI group. Patient and graft survival was 100% and 99% in the belatacept and CNI groups, respectively.26

Adverse effects

Malignancy

The largest belatacept trial to date, the Phase III BENEFIT trial, found that the incidence of malignancy in belatacept was dramatically higher than that of cyclosporin.22 Of the 445 patients receiving belatacept, 11 developed malignancy (2.5%) compared with only one patient of the 221 patients receiving cyclosporin (0.5%). Perhaps more importantly, 5 of the 11 patients in the belatacept who developed malignancy in the belatacept arms were diagnosed with post-transplant lymphoproliferative disorder (PTLD), two of which involved the central nervous system (CNS). Of the 359 patients enrolled in the two belatacept groups in the BENEFIT-EXT Phase III trial, eight (2.2%) developed malignancy.24 In comparison, six patients (3.3%) in the cyclosporin group developed cancer. However, five of the eight patients in the belatacept group were diagnosed with PTLD, four of which involved the CNS. The Phase II trial published by Vincenti and his colleague reported two (1.4%) cases of malignancy, one of which was diagnosed as PTLD, in the belatacept arm compared with two (2.7%) malignancies in the cyclosporin arm.19 Additionally, two more cases of PTLD were diagnosed in the MI dosing group 2 and 13 months after the trial had closed and the patients had been switched to conventional immunosuppressive regimens.

Of the three major trials described above, a total of 13 patients in the belatacept groups have been diagnosed with PTLD (1.4%) compared with only one cyclosporin patient (0.2%).19,22,24 Of the 13 cases of PTLD identified, six developed PTLD of the CNS. This is a concerning diagnosis, considering that only three case series have documented a total of 45 patients with PTLD involving the CNS in SOT.27-29
The majority of patients who developed PTLD had known risk factors for PTLD, including EBV seronegative recipients pre-transplant, receiving lymphocyte-cell-depleting agents, and having a primary EBV infection. A recent Phase II analysis that excluded transplant recipients who were EBV seronegative pre-transplant has yet to report any cases of PTLD. The absence of PTLD in this analysis may be evidence enough to avoid use of belatacept in those recipients who are EBV seronegative pre-transplant.

**Infectious complications**

Incidence of CMV infection was found to be similar when comparing the MI, LI, and cyclosporin groups regardless of analysis. CMV was diagnosed in a total of 96 belatacept patients (10.1%) compared with 56 (11.7%) cyclosporin patients in the three pivotal belatacept trials. Urinary tract infections (UTI), ranging from minor to severe, were the most common infectious complication noted, occurring in 263 (29.1%) of the 949 belatacept patients with available data. Each analysis determined that the incidence of UTI was similar in the belatacept groups when compared with the cyclosporin arms.

The Phase III trials reported on similar infectious outcomes. Both the BENEFIT and BENEFIT-EXT trials determined that there were no differences in the incidence of fungal infections, BK virus, pneumonia, upper respiratory infection, and infectious gastroenteritis when comparing the MI and LI belatacept arms with cyclosporin. However, the BENEFIT-EXT trial did report a single case of pneumocystis jirovecii pneumonia in both the LI and MI belatacept arms. Also, a single case of progressive multifocal leukoencephalopathy (PML) was also reported in a patient who was enrolled in the MI group after completion of the 12 month analysis.

**Cardiovascular and metabolic**

An anticipated benefit of belatacept compared with a CNI based regimen, aside from improvements in GFR over time, is the avoidance of adverse metabolic outcomes. The BENEFIT trial demonstrated a decrease in triglyceride levels from baseline for both the MI (−17.0 ± 7.0 mg/dL; \( P = 0.0165 \)) and LI (−21.2 ± 6.9 mg/dL; \( P = 0.0047 \)) belatacept groups compared with an increase in the cyclosporin group (6.6 ± 6.9 mg/dL). Triglycerides were also found to decrease in the MI (−1.0 ± 9.5 mg/dL; \( P = 0.0106 \)) and LI (−18.2 ± 9.2 mg/dL; \( P = 0.0001 \)) belatacept groups compared with a cyclosporin increase in the BENEFIT-EXT trial.

An increase in non-HDL cholesterol from baseline was seen in all three groups in the BENEFIT trial; however, they were less severe in the MI (8.1 ± 2.8 mg/dL; \( P = 0.0115 \)) and LI (8.0 ± 2.8 mg/dL; \( P = 0.0104 \)) belatacept groups compared with cyclosporin (18.3 ± 2.8 mg/dL). The BENEFIT-EXT trial also found that non-HDL cholesterol in the cyclosporin arm (29.3 ± 3.8 mg/dL; \( P = 0.0016 \)) had increased significantly from baseline when compared with the MI (12.6 ± 3.6 mg/dL; \( P = 0.0016 \)) and LI (11.2 ± 3.6 mg/dL; \( P = 0.0006 \)) belatacept groups.

Mean systolic blood pressure was significantly reduced in both the MI (133 ± 16.2 mmHg; \( P = 0.001 \)) and LI (131 ± 16.5 mmHg; \( P = 0.0001 \)) regimens compared with cyclosporin (139 ± 20.1 mmHg) in the BENEFIT trial. Diastolic blood pressure also improved in the MI (79 ± 11.6 mmHg; \( P = 0.0273 \)) and LI (79 ± 10.9 mmHg; \( P = 0.005 \)) belatacept groups compared to cyclosporin (82 ± 11.2 mmHg). Finally, incidence of new onset diabetes after transplant (NODAT) occurred in 28 (3.5%) of the 804 belatacept patients included in both the BENEFIT and BENEFIT-EXT trials compared with 27 (6.7%) of the 405 cyclosporin patients included.

**Infusion related reactions**

Acute infusion-related adverse events, defined as a reaction within the first hour of infusion, occurred in 24 (2.5%) of the 949 belatacept patients studied. However, the BENEFIT-EXT trial also found that non-HDL cholesterol in the cyclosporin arm (29.3 ± 3.8 mg/dL; \( P = 0.0016 \)) had increased significantly from baseline when compared with the MI (12.6 ± 3.6 mg/dL; \( P = 0.0016 \)) and LI (11.2 ± 3.6 mg/dL; \( P = 0.0006 \)) belatacept groups.

**Discussion**

Belatacept is a novel immunosuppressive agent that offers a potential new option for prophylaxis of ACR in RTR. The mechanism of action is unique compared with currently available immunosuppressives in that costimulation required for T-cell activation is inhibited. If approved, belatacept would be the first biologic compound developed for the purpose of maintenance immunosuppression in SOT.

The increased rates and severity of ACR demonstrated in the belatacept groups requires careful consideration. It is well documented that early onset ACR in the months immediately following renal transplantation is one of the most substantial predictors for poor long-term allograft
function and survival. However, more recently published data suggest that despite a decrease in overall ACR rates and severity, trends in long-term graft function remain unchanged. This phenomena might be explained by the acute and chronic nephrotoxic effects that are associated with current immunosuppressive regimens. The 13–15 mL/min improvement in GFR seen with belatacept patients compared with cyclosporin could potentially correlate with improved long-term outcomes despite the increased incidence of ACR. However, long-term results of allograft function and survival from the belatacept Phase III trials previously described are required before any conclusions on long-term outcomes can be established.

Malignancy notwithstanding, the safety profile of belatacept appears to be relatively benign. Significant improvements in metabolic and cardiovascular risk factors compared with Cyclosporin make belatacept an attractive option, especially in an end-stage renal disease population with an increased risk of death due to cardiovascular complications. Avoidance of infectious complications, including bacterial, CMV, BK virus, and fungal infections has not favored any one agent.

The increased incidence of malignancy documented with belatacept use is of critical concern. More specifically, the 13 cases of PTLD among 949 patients receiving belatacept compared with only one case in 478 cyclosporin-treated patients demands notice. An even more troubling trend is that 6 of the 13 PTLD cases had CNS involvement. The incidence of malignancy documented with belatacept use is of critical concern. More specifically, the 13 cases of PTLD among 949 patients receiving belatacept compared with only one case in 478 cyclosporin-treated patients demands notice. An even more troubling trend is that 6 of the 13 PTLD cases had CNS involvement. An explanation for this association remains elusive. However, avoidance of known risk factors has demonstrated a significant reduction in the incidence of PTLD. A small analysis excluding RTR who were EBV naïve at time of transplant (n = 59) has not resulted in any documented cases of PTLD. Interestingly, all of the patients received T-cell-depleting induction therapy which is a known risk factor for development of PTLD. At this time, belatacept use may be warranted in those patients who are EBV naïve and may benefit from belatacept as a rescue therapy with appropriate monitoring and prophylaxis for PTLD. Increased rates of ACR, seen with belatacept, are typically associated with a decreased incidence of malignancy in solid organ transplantation. Belatacept seems to defy this reasoning by causing an increased incidence in both ACR and malignancy when compared with cyclosporin. Unfortunately, a cause for this atypical relationship has not been determined but requires attention when administering belatacept.

The incidence of PTLD is being reviewed by the FDA during the approval process. In March 2010, the FDA’s Cardiovascular and Renal Drugs Advisory Committee voted to recommend the approval of belatacept, but it also recommended that belatacept be approved with a risk evaluation and mitigation strategy (REMS) program due to the risk of PTLD and infectious complications. The recommended belatacept REMS program would aim to manage these risks. The proposed elements of this REMS program would include both a patient medication guide and a healthcare provider (HCP) communication plan. The goals of the proposed belatacept REMS would be to minimize the risk of PTLD and serious infections by educating HCPs and patients on the risk of their occurrence and ways to mitigate the impact of these adverse events should they occur. In addition, a thorough pharmacovigilance plan has been proposed that includes routine and enhanced safety monitoring, as well as four postmarketing research studies aimed at further characterizing these risks.

In May 2010, the FDA delayed approval of this medication and asked the manufacturer to provide 36-months of follow-up data from the Phase III clinical studies to further evaluate the long-term effects of belatacept. The FDA also asked for information to support the manufacturer’s proposed REMS. It is safe to say that when and if belatacept is approved by the FDA then it will require a REMS program.

Belatacept’s role as a rescue therapy has been described in patient’s suffering from mammalian target of rapamycin associated adverse effects, CNI-associated posttransplant thrombotic microangiography, and hemolytic uremic syndrome. Successful transition of a CNI-based immunosuppressive regimen to a belatacept-based regimen has previously been described. If approved by the FDA, belatacept’s most immediate role might be that of a rescue therapy when traditional immunosuppressive regimens prove intolerable. It is important to note that a switch in immunosuppressive therapy from a CNI to belatacept does carry an increased risk of ACR as described in the analysis.

The majority of trials summarized in this review combine belatacept with basiliximab induction therapy as well as mycophenolate mofetil and steroids for long-term maintenance immunosuppression. Ferguson et al performed an analysis that coupled belatacept with rabbit-antithymocyte globulin induction and a steroid withdrawal protocol. As previously discussed, the use of rabbit-antithymocyte globulin is associated with an increase in both malignancy
The analysis only included RTRs who were known to be EBV seropositive pre-transplant. At the time of this review, no cases of PTLD have been described in either the B+SRL or B+MMF groups in this study. The two belatacept groups have also demonstrated similar rates of infection when compared with the standard TAC+MMF group. Use of rabbit-antithymocyte globulin as an induction therapy is a reasonable option for patients planned for long-term belatacept therapy if they are EBV seropositive prior to transplantation.

A clear disadvantage to CNI-based immunosuppressive regimens is the obligation of TDM. Constant intra- and interpatient pharmacokinetic variability insist that clinicians and patients remain diligent about appropriately drawing levels, avoiding food and drug interactions that potentially inhibit or induce drug metabolism, and constantly document changes in dosing throughout the life of the allograft. Barriers to TDM in both the outpatient and inpatient realms have been thoroughly described. These barriers are potentially avoided with the use of belatacept in that the pharmacokinetic profile demonstrates linear, zero-order elimination regardless of age, gender, or organ function. Pharmacodynamic monitoring of belatacept’s saturation of the CD86 site on APCs has been described as a potentially meaningful assessment of effectiveness. However, no clinical trials of belatacept have implemented TDM as means of immunosuppressive management in patient and is therefore not recommended.

An obvious disadvantage of belatacept is the requirement of a local infusion-center, a hired home infusion service, or an infusion suite within a transplant center’s clinic for administration. Without these essential resources, the use of belatacept is irrelevant. Patients and centers that have access to meet the appropriate infusion requirements have an opportunity to overcome issues of medication adherence. The requirement of monthly infusions at a local center could potentially lead to improved adherence to an immunosuppressive medication because a missed appointment is immediately recognized by clinicians. However, ensured adherence to oral medications that compliment belatacept-based immunosuppression cannot be guaranteed. Estimates of nonadherence in the transplant population range from 5% to 55% of all patients, and the impact of requiring one medication to be given as an infusion is arguable.

The financial impact belatacept will have on the renal transplant patient, healthcare system, and both private and public insurance is difficult to discern. Both the preparation and administration require resources and facilities that provide the appropriate sterile environments that comply with current standards. Furthermore, the infusions should only be administered by staff that are both qualified and certified to do so. The cost of belatacept itself is undetermined at the time of this review. However, the incremental dosing of belatacept, one infusion every 4 weeks, may ease any financial burden on the patient and associated healthcare systems. An assessment of belatacept’s pharmacokinetic profile after subcutaneous administration is currently being executed. Unfortunately, there are no available data from this analysis at the time of this review. If subcutaneous administration of belatacept is found to have a comparable pharmacokinetic profile with the IV administration it would introduce a potential bypass to many of belatacept’s logistical disadvantages. For example, local-infusion centers, home infusion services, or need of an infusion suite would no longer be necessary. Self-administration of a subcutaneous injection would presumably soften the economic impact of belatacept and improve patients’ quality of life.

Currently, based on the manufacturer’s recommendation, the FDA is reviewing the LI dosing regimen of belatacept as an immunosuppressive regimen in kidney transplant recipients. The potential introduction of a novel biologic agent that offers a new mechanism of inhibiting cellular response is an exciting development in a field that has exhausted the current options. Although improvements in renal function have been well documented and are promising, the increased risk of ACR and malignancy associated with belatacept are certainly troubling. Unfortunately, the availability of long-term efficacy and safety outcomes is limited. The FDA has appropriately postponed a decision on belatacept’s introduction to the market until such data does become available. If approved, caution in patients who are at an increased risk of malignancy, especially PTLD, is paramount. Also, despite improvements in allograft function compared with standard regimens, clinicians will be accepting an increased risk in the incidence and severity of ACR.

Disclosure
The authors do not have any disclosures in regards to the content of this manuscript.

References
16. 4.
17. 5.
18. 6.
19. 7.
20. 8.
21. 9.
22. 10.
23. 11.
24. 12.
25. 13.
27. 15.
28. 16.
29. 17.
30. 18.
31. 19.
32. 20.
33. 21.
34. 22.
35. 23.
36. 24.
37. 25.
38. 26.
39. 27.
40. 28.
41. 29.
42. 30.
43. 31.
44. 32.
45. 33.
46. 34.
47. 35.
48. 36.
49. 37.
50. 38.
51. 39.
52. 40.